SULFISCON

The founders discovered that modulating cellular H2S levels inhibited pathologic calcification in animal models. We searched for small molecules that are allosteric modulators of H2S synthesis and have identified candidate molecules that are undergoing medicinal chemistry development and we plan to bring a new drug to market within the next 5 years. There is no current cure for pathologic calcification. Founding team consists of Alexander So, Sonia Nasi and Nathalie Busso. All worked or are still working for the CHUV (Service of Rheumatology). The market size for genetic disorders of pathologic calcification is around 100K patients in UK and EU, and for rare skin disorders of calcification around 300K patients.